Taking the fight against high drug prices into their own hands, Maryland lawmakers passed a bill aimed at taking on “unconscionable” pricing practices with their sights set squarely on generics. However, drug makers are blasting back, hoping to convince the governor not to sign it into law.
Under fire from all sides for high drug stickers and price hikes, pharma has put R&D costs front and center in its defense. But a secondary argument—or attempt to shift the blame, depending on your point of view—might be more effective, if it managed to find its way into the spotlight.
One of FDA’s most strategic outposts is in India, the seventh largest supplier of food and second largest supplier of pharmaceuticals and biologics to the United States. The Agency’s office, located in the capital, New Delhi, works to ensure the safety and security of food and the safety and efficacy of medical products exported from India to the U.S.
A bipartisan bill that plans to allow a tax credit for expenses of contracted research — often done by Contract Research Organizations (CROs) — has been introduced in the U.S. House of Representatives and was quickly hailed by the industry.
Former FDA Commissioner Robert Califf and his successor Scott Gottlieb have applauded President Donald Trump’s decision to keep Francis Collins as head of the National Institutes of Health (NIH), although it may be a poisoned chalice given that billions of dollars in cuts could be on the way.
Researchers at ITMO University in St. Petersburg, Russia, have developed a magnetically controlled treatment designed to dissolve blood clots. The method looks to be a promising solution to some of the complications associated with enzyme-based thrombolytic drugs.
After President Donald Trump’s blueprint budget in March looked to cut $5.8 billion from the National Institutes of Health (NIH), his administration is now looking for an immediate $1.2 billion in cuts from the medical research network in FY 2017.